Expression and functional analysis of dopamine receptor subtype 2 and somatostatin receptor subtypes in canine Cushing's disease

Endocrinology

Volumn 149, Issue 9, 2008, Pages 4357-4366

  De Bruin, C ^a   Hanson, J M ^b   Meij, B P ^b   Kooistra, H S ^b   Waaijers, A M ^a   Uitterlinden, P ^a   Lamberts, S W J ^a   Hofland, L J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DEXAMETHASONE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; MIFEPRISTONE; OCTREOTIDE; PASIREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5;

ACTH SECRETING ADENOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CUSHING DISEASE; DOG; DRUG EFFECT; FEMALE; HYPERCORTISOLISM; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSSPHENOIDAL ADENOMECTOMY; TRANSSPHENOIDAL HYPOPHYSECTOMY;

ACTH-SECRETING PITUITARY ADENOMA; ADENOMA; ANIMALS; CELLS, CULTURED; DEXAMETHASONE; DOG DISEASES; DOGS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; MALE; PITUITARY ACTH HYPERSECRETION; PROTEIN ISOFORMS; RECEPTORS, DOPAMINE D2; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER;

EID: 50449084779     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-0244     Document Type: Article

References (50)

1. Orth DN 1995 Cushing's syndrome. N Engl J Med 332:791-803
2. Melby JC 1988 Therapy of Cushing disease: a consensus for pituitary microsurgery. Ann Intern Med 109:445-446
3. Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B 2005 Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol (Oxf) 63:549-559
4. Morris D, Grossman A 2002 The medical management of Cushing's Syndrome. Ann NY Acad Sci 970:119-133
5. Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SW 2005 The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152:645-654
6. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SW 2004 Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89:2452-2462
7. Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A 2006 The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 91:4482-4488
8. Boscaro M, Petersenn S, Atkinson AB, Bertherat J, Findling J, Snyder P, McBride K, Reincke M, Ludlam W, Gao B, Melmed S, Freda P, Frohman L, Grossman A, Biller B, Glusman JE Pasireotide (SOM230), the novel multi-ligand somatostatin analogue, is a promising medical therapy for patients with Cushing's disease: preliminary safety and efficacy results of a phase II study. Program of the 88th Annual Meeting of The Endocrine Society, Boston, MA, 2006, p 81 (Abstract OR9-1)
9. Etxabe J, Vazquez JA 1994 Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 40:479-484
10. Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J 2001 Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab 86:117-123
11. Katznelson L, Bogan JS, Trob JR, Schoenfeld DA, Hedley-Whyte ET, Hsu DW, Zervas NT, Swearingen B, Sleeper M, Klibanski A 1998 Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas. J Clin Endocrinol Metab 83:1619-1623
12. Bochicchio D, Losa M, Buchfelder M 1995 Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group. J Clin Endocrinol Metab 80:3114-3120
13. Rijnberk A, der Kinderen PJ, Thijssen JH 1968 Spontaneous hyperadrenocorticism in the dog. J Endocrinol 41:397-406
14. Willeberg P, Priester WA 1982 Epidemiological aspects of clinical hyperadrenocorticism in dogs (canine Cushing's syndrome). J Am Anim Hosp Assoc 18:717-724
15. McNicol AM, Thomson H, Stewart CJ 1983 The corticotrophic cells of the canine pituitary gland in pituitary-dependent hyperadrenocorticism. J Endocrinol 96:303-309
16. El Etreby MF, Muller-Peddinghaus R, Bhargava AS, Trautwein G 1980 Functional morphology of spontaneous hyperplastic and neoplastic lesions in the canine pituitary gland. Vet Pathol 17:109-122
17. Kemppainen RJ, Peterson ME 1994 Animal models of Cushing's disease. Trends Endocrinol Metab 5:21-28
18. Hanson JM, Teske E, Voorhout G, Galac S, Kooistra HS, Meij BP 2007 Prognostic factors for outcome after transsphenoidal hypophysectomy in dogs with pituitary-dependent hyperadrenocorticism. J Neurosurg 107:830-840
19. den Hertog E, Braakman JC, Teske E, Kooistra HS, Rijnberk A 1999 Results of non-selective adrenocorticolysis by o,p′-DDD in 129 dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 144:12-17
20. Barker EN, Campbell S, Tebb AJ, Neiger R, Herrtage ME, Reid SW, Ramsey IK 2005 A comparison of the survival times of dogs treated with mitotane or trilostane for pituitary-dependent hyperadrenocorticism. J Vet Intern Med 19:810-815
21. Meij BP, Voorhout G, van den Ingh TS, Hazewinkel HA, Teske E, Rijnberk A 1998 Results of transsphenoidal hypophysectomy in 52 dogs with pituitary-dependent hyperadrenocorticism. Vet Surg 27:246-261
22. Meij BP, Voorhout G, Van den Ingh TS, Hazewinkel HA, Van't Verlaat JW 1997 Transsphenoidal hypophysectomy in beagle dogs: evaluation of a microsurgical technique. Vet Surg 26:295-309
23. Rijnberk A, van Wees A, Mol JA 1988 Assessment of two tests for the diagnosis of canine hyperadrenocorticism. Vet Rec 122:178-180
24. Stolp R, Rijnberk A, Meijer JC, Croughs RJM 1983 Urinary corticoids in the diagnosis of canine hyperadrenocorticism. Res Vet Sci 34:141-144
25. Meij B, Voorhout G, Rijnberk A 2002 Progress in transsphenoidal hypophysectomy for treatment of pituitary-dependent hyperadrenocorticism in dogs and cats. Mol Cell Endocrinol 197:89-96
26. Hanson JM, van 't HM, Voorhout G, Teske E, Kooistra HS, Meij BP 2005 Efficacy of transsphenoidal hypophysectomy in treatment of dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 19:687-694
27. van der Vlugt-Meijer RH, Voorhout G, Meij BP 2002 Imaging of the pituitary gland in dogs with pituitary-dependent hyperadrenocorticism. Mol Cell Endocrinol 197:81-87
28. Bosje JT, Rijnberk A, Mol JA, Voorhout G, Kooistra HS 2002 Plasma concentrations of ACTH precursors correlate with pituitary size and resistance to dexamethasone in dogs with pituitary-dependent hyperadrenocorticism. Domest Anim Endocrinol 22:201-210
29. Rijnberk A, Mol JA, Rothuizen J, Bevers MM, Middleton DJ 1987 Circulating pro-opiomelanocortin-derived peptides in dogs with pituitary-dependent hyperadrenocorticism. Front Horm Res 17:48-60
30. Voorhout G, Rijnberk A, Sjollema BE, van den Ingh TS 1990 Nephrotomography and ultrasonography for the localization of hyperfunctioning adrenocortical tumors in dogs. Am J Vet Res 51:1280-1285
31. Kooistra HS, Voorhout G, Mol JA, Rijnberk A 1997 Correlation between impairment of glucocorticoid feedback and the size of the pituitary gland in dogs with pituitary-dependent hyperadrenocorticism. J Endocrinol 152:387-394
32. Hanson JM, Kooistra HS, Mol JA, Teske E, Meij BP 2006 Plasma profiles of adrenocorticotropic hormone, cortisol, α-melanocyte- stimulating hormone, and growth hormone in dogs with pituitary-dependent hyperadrenocorticism before and after hypophysectomy. J Endocrinol 190:601-609
33. Meij BP, Mol JA, van den Ingh TS, Bevers MM, Hazewinkel HA, Rijnberk A 1997 Assessment of pituitary function after transsphenoidal hypophysectomy in beagle dogs. Domest Anim Endocrinol 14:81-97
34. Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely AJ, Beckers A, Lamberts SW 2004 The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 89:1577-1585
35. Rasmussen R 2001 Quantification on the LightCycler. In: Meuer S, Wittwer C and Nakagawara K, eds. Rapid cycle real-time PCR, methods and applications. Heidelberg: Springer Press; 21-34
36. Pfaffl MW 2001 A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45
37. Bhatti SF, De Vliegher SP, Mol JA, Van Ham LM, Kooistra HS 2006 Ghrelin-stimulation test in the diagnosis of canine pituitary dwarfism. Res Vet Sci 81:24-30
38. Brinkhof B, Spee B, Rothuizen J, Penning LC 2006 Development and evaluation of canine reference genes for accurate quantification of gene expression. Anal Biochem 356:36-43
39. Oyama K, Sanno N, Teramoto A, Osamura RY 2001 Expression of neuro D1 in human normal pituitaries and pituitary adenomas. Mod Pathol 14:892-899
40. Poulin G, Turgeon B, Drouin J 1997 NeuroD1/β2 contributes to cell-specific transcription of the proopiomelanocortin gene. Mol Cell Biol 17:6673-6682
41. Hanson JM, Mol JA, Meij BP 2007 Differential expression of neurogenic differentiation 1 (NeuroD1) in the canine pituitary gland and corticotroph adenomas. In: Pathobiology and oncogenesis of pituitary corticotroph adenomas in dogs, thesis. Atalanta, Houten, The Netherlands; 161-171
42. Hofland LJ, Liu Q, Van Koetsveld PM, Zuijderwijk J, Van Der Ham F, De Krijger RR, Schonbrunn A, Lamberts SW 1999 Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. J Clin Endocrinol Metab 84:775-780
43. Bilodeau S, Vallette-Kasic S, Gauthier Y, Figarella-Branger D, Brue T, Berthelet F, Lacroix A, Batista D, Stratakis C, Hanson J, Meij B, Drouin J 2006 Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev 20:2871-2886
44. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707-716
45. Castillo VA, Gomez NV, Lalia JC, Cabrera Blatter MF, Garcia JD 2008 Cushing's disease in dogs: cabergoline treatment. Res Vet Sci 85:26-34
46. van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW, Hofland LJ 2005 Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 289:E278 -E287
47. Schmid HA 2008 Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 286:69-74
48. Heaney AP, Melmed S 2004 Molecular targets in pituitary tumours. Nat Rev Cancer 4:285-295
49. Paez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E, Losa M, Stalla J, Grubler Y, Missale C, Arzt E, Stalla GK 2001 Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 108:1123-1131
50. Castillo V, Giacomini D, Paez-Pereda M, Stalla J, Labeur M, Theodoropoulou M, Holsboer F, Grossman AB, Stalla GK, Arzt E 2006 Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology 147:4438-4444